CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
June 06, 2024 12:14 ET
|
CG Oncology Inc.
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab
Ipsen - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
June 06, 2024 12:00 ET
|
Ipsen Pharma
Information mensuelle relative au nombre total des droits de voteet d’actions composant le capital social (conformément à l’article L.233-8 II du Code de commerceet à l’article 223-16 du...
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital
June 06, 2024 12:00 ET
|
Ipsen Pharma
Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16...
Information marché Financement du projet de transformation FOCUS-27
June 06, 2024 11:54 ET
|
Euroapi
Communiqué de presse Paris – Le 6 juin 2024 – EUROAPI informe avoir décidé de se faire accompagner par un mandataire ad hoc dans les discussions entamées en février 2024 concernant le financement à...
Market update : FOCUS-27 transformation project financing
June 06, 2024 11:54 ET
|
Euroapi
Press release Paris – June 6, 2024 – EUROAPI informs that it has decided to be assisted by a mandataire ad hoc in its discussions initiated in February 2024 regarding the mid-term and long-term...
Los regímenes basados en DARZALEX® (daratumumab) mejoraron significativamente los resultados clínicos tanto en pacientes con mieloma múltiple de nuevo diagnóstico candidatos a trasplante como en los no candidatos
June 06, 2024 11:31 ET
|
Janssen Cilag International NV
El 88 por ciento de los pacientes candidatos a trasplante lograron una respuesta completa o mejor, y el 47 por ciento de los pacientes mantuvieron la negatividad de la ERM durante más de un año con...
La Fondation ACT salue la décision du ministre de l'Éducation du Québec d’étendre les défibrillateurs à toutes les écoles publiques
June 06, 2024 11:27 ET
|
La Fondation ACT
OTTAWA, 06 juin 2024 (GLOBE NEWSWIRE) -- La Fondation (ACT) des soins avancés en urgence coronarienne accueille favorablement l’annonce faite par le ministre de l'Éducation, Bernard Drainville,...
ACT Foundation congratulates Quebec Minister of Education on announcement to expand AEDs to all public schools
June 06, 2024 11:27 ET
|
ACT Foundation of Canada
OTTAWA, June 06, 2024 (GLOBE NEWSWIRE) -- The Advanced Coronary Treatment (ACT) Foundation congratulates Education Minister Bernard Drainville for his announcement to ensure Automated External...
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
June 06, 2024 11:15 ET
|
Arbutus Biopharma Corporation
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation...
Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B
June 06, 2024 11:15 ET
|
Barinthus Biotherapeutics
Barinthus Bio presents updated data from two clinical trials in people with chronic hepatitis B at EASL Congress 2024.